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Background: Non-HIV Pneumocystis pneumonia (PCP) can occur in immunosuppressed patients having malignancy
or on immunosuppressive agents. To classify severity, the A-DROP scale proposed by the Japanese Respiratory
Society (JRS), the CURB-65 score of the British Respiratory Society (BTS) and the Pneumonia Severity Index (PSI) of
the Infectious Diseases Society of America (IDSA) are widely used in patients with community-acquired pneumonia
(CAP) in Japan. To evaluate how correctly these conventional prognostic guidelines for CAP reflect the severity of
non-HIV PCP, we retrospectively analyzed 21 patients with non-HIV PCP.
Methods: A total of 21 patients were diagnosed by conventional staining and polymerase chain reaction (PCR) for
respiratory samples with chest x-ray and computed tomography (CT) findings. We compared the severity of 21
patients with PCP classified by A-DROP, CURB-65, and PSI. Also, patients’ characteristics, clinical pictures, laboratory
results at first visit or admission and intervals from diagnosis to start of specific-PCP therapy were evaluated in both
survivor and non-survivor groups.
Results: Based on A-DROP, 18 patients were classified as mild or moderate; respiratory failure developed in 15 of
these 18 (83.3%), and 7/15 (46.7%) died. Based on CURB-65, 19 patients were classified as mild or moderate;
respiratory failure developed in 16/19 (84.2%), and 8 of the 16 (50%) died. In contrast, PSI classified 14 as severe or
extremely severe; all of the 14 (100%) developed respiratory failure and 8/14 (57.1%) died. There were no significant
differences in laboratory results in these groups. The time between the initial visit and diagnosis, and the time
between the initial visit and starting of specific-PCP therapy were statistically shorter in the survivor group than in
the non-survivor group.
Conclusions: Conventional prognostic guidelines for CAP could underestimate the severity of non-HIV PCP,
resulting in a therapeutic delay resulting in high mortality. The most important factor to improve the mortality of
non-HIV PCP is early diagnosis and starting of specific-PCP therapy as soon as possible.
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Table 1 Characteristics of PCP patients without HIV







Rheumatic and autoimmune diseases 12 57.1
Malignancy 10 47.6
Diabetes mellitus 4 19.0
Chronic pulmonary diseases 6 28.6
Heart diseases 4 19.0
Cerebrovascular diseases 2 9.5
Renal diseases 2 9.5
Liver disease 2 9.5
Long-term glucocorticoids alone 4 19.0





PCP prophylaxis 1 4.8
Table 1 legend - PCP, Pneumocystis pneumonia; SD, standard deviation.
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Pneumocystis pneumonia (PCP) not related to human
immunodeficiency virus (HIV) can occur in immunosup-
pressed patients having malignancy or on immunosup-
pressive agents [1-10]. The mortality of patients with
PCP without HIV infections ranges from 0 to 70% [1,3-10],
compared to that of HIV-infected PCP patients, which
ranges from 10 to 20% [1,4,9]. Besides, mortality rates as
high as 60–75% have been reported in PCP patients
without AIDS who required mechanical ventilation
[11,12]. The higher mortality among non-HIV PCP
patients has been attributed to severe lung inflammation
[1,4,10], although the exact etiology accounting for these
large differences in mortality has not yet been determined.
The A-DROP system proposed by the Japanese Respira-
tory Society (JRS), the CURB-65 score proposed by British
Respiratory Society (BTS) and the Pneumonia Severity
Index (PSI) proposed by the Infectious of Disease Society
of America (IDSA) are widely used in classifying patients
with community-acquired pneumonia (CAP) [13-15] in
Japan. For the purpose of evaluating how correctly the con-
ventional prognostic guidelines of CAP reflect the severity
of non-HIV PCP, we retrospectively analyzed 21 patients
with non-HIV PCP. It has never previously been reported
that the severity of non-HIV PCP may be underestimated
by these prognostic guidelines. This is the first report fo-
cusing on the limit of conventional prognostic guidelines of
CAP for non-HIV PCP.
Methods
From the end of 2009 to the beginning of 2010 we retro-
spectively reviewed all the cases of PCP diagnosed as
CAP in the Kameda Medical Center, Chiba, Japan. All
the patients had undergone HIV testing and were nega-
tive. Patients with hospital associated pneumonia (HAP)
were excluded. PCP was diagnosed based on polymerase
chain reaction (PCR) and conventional PCP staining with
Grocott methenamine silver stain or Diff-Quick™ staining
in respiratory samples such as induced sputum (IS) or
bronchoalveolar lavage (BAL) fluid associated with radio-
graphic infiltration on chest X-ray and computed tomog-
raphy (CT) findings on admission. All radiographic pictures
showed infiltration confirmed by the pulmonologist and
radiologist in our hospital. The decision to perform IS or
BAL examination depended on the patient’s general condi-
tion at the discretion of attending physicians. PCP diagnosis
was based not solely on the positive PCR respiratory speci-
men but also on the clinical and radiological findings con-
sistent with the diagnosis of PCP as well as complete
recovery with anti-Pneumocystis jirovecii treatment alone.
No biopsy was performed during this study. We compared
the severity of 21 patients with PCP classified by A-DROP,
CURB-65, and PSI, and analyzed the background and la-
boratory data of each.Statistical analysis
Comparisons of group means were made by unpaired or
paired t-tests or Mann–Whitney U-test. Contingency
tables were evaluated by Fisher’s exact probability test.
p values< 0.05 were considered significant.
Results
Patient characteristics
The characteristics of the 21 patients with PCP are
shown in Tables 1 and 2. The mean age was 71.5 years
(range 57–88). Twelve patients (57.1%) had rheumatic or
autoimmune disease which was the most common under-
lying disease, followed by malignancy (n = 10, 47.6%).
Seventeen patients (77.8%) were receiving steroid or
immunosuppressants for the underlying disease. Prophy-
lactic therapy consisting of trimethoprim-sulfamethoxazole
(TMP/SMX) was used by only 1 patient (4.8%).
Treatment and outcomes
All the patients received oral or parenteral (TMP/SMX
and adjuvant steroid therapy. Eighteen (85.7%) of the 21
patients had acute respiratory failure. Eight patients
(38.1%) in the study died.
Severity of PCP by A-DROP
The A-DROP scale was one of the prognostic guidelines for
CAP proposed by JRS in 2005. It is a scoring system using
age, degree of dehydration (serum blood urea nitrogen
(BUN)), SpO2< 90%(PaO2< 60 mm Hg), orientation, and


















Renal disease 1 1 1.000
Liver disease 2 0 0.505
Table 2 legend -Presented data are evaluated by Fisher’s exact test.
Asai et al. Multidisciplinary Respiratory Medicine 2012, 7:2 Page 3 of 6
http://www.mrmjournal.com/content/7/1/2systolic blood pressure. All our patients were classified by
the A-DROP system. As a result, 18 patients (85.7%) were
classified as mild or moderate. Fifteen (83.3%) of the 18
developed respiratory failure, and 7 (46.7%) of the 15 died
(Table 3).Severity of PCP by CURB-65
CURB-65 is also a prognostic guideline for CAP, proposed
by BTS in 1996. It seems to be similar to the A-DROP sys-
tem, the greatest difference being the age value used in the
scoring. While JRS defines males> 70 years and females>
75 years as high risk elderly, BTS classifies high risk elderlyTable 3 Distribution of patients and their mortality











A-DROP 0 5 (23.8) 3 (60) 0 (0)
1 6 (28.6) 5 (83.3) 2 (33.3)
2 7 (33.3) 7 (100) 5 (71.4)
3 2 (9.5) 2 (100) 1 (50)
4/5 1 (4.8) 1 (100) 0 (0)
CURB-65 0 4 (19) 2 (50) 0 (0)
1 3 (14.3) 2 (66.7) 0 (0)
2 12 (57.1) 12 (100) 8 (66.7)
3 0 (0)
4/5 2 (9.5) 2 (100) 0 (0)
PSI* I 0 (0)
II 4 (19) 2 (50) 0 (0)
III 3 (14.3) 2 (66.7) 1 (33.3)
IV 12 (57.1) 12 (100) 6 (50)
V 2 (9.5) 2 (100) 1 (50)
*In PSI, relations of risk classes to net points are as follows:
I: 0, II: 1–70, III: 71–90, IV: 91–130, V: >131.
Table 3 legend - PCP, Pneumocystis pneumonia; PSI, pulmonary severity index.age as> 65 years for both sexes. In our study 19 patients
(90.5%) were classified as mild or moderate (class 0–2);
16 of the 19 patients (84.2%) developed acute respiratory
failure, and 8 (42.1%) of the 16 died (Table 3).
Severity of PCP by PSI
The PSI was proposed by the Infectious Diseases Society
of America/American Thoracic Society (IDSA/ATS). It is
considered to be more complicated and less convenient
to use than the other scoring systems. It consists of 19
items such as age, underlying disease, gender, vital signs,
etc. In our study, 14 patients (66.7%) were classified as
severe or extremely severe by PSI. All the 14 patients
developed respiratory failure and 7 patients (50%) died
(Table 3).
Distribution of patients and their mortality in each risk
class of A-DROP, CURB-65 and PSI
The majority of the PCP patients were categorized in
risk classes 2–3 by A-DROP and CURB-65, and III/IV
by PSI. Of note are the very high patient mortalities in
risk classes 2 by A-DROP and CURB-65, and class III/IV
by PSI (Table 3).
Comparison of the prognostic accuracy between A-DROP,
CURB-65 and PSI
The comparison of the prognostic accuracy of each
guideline for CAP is shown in Table 4. It can be seen
that the positive predictive values and negative predictive
values for mortality in each system were low.
Comparison of the characteristics between survivors and
non survivors
The lactate dehydrogenase (LDH) value tended to be
higher and Alb/BUN tended to be lower in the non sur-
vivor group compared with the survival group, but this
was not statistically significant. There were no significant
differences in serum β-D-glucan (β-DG), Krebs von den
Lungen 6 (KL-6), body mass index (BMI) between the
two groups. However, both the time between the initial
visit and establishment of a diagnosis and the time be-
tween the initial visit and starting PCP therapy were sig-
nificant much shorter in the survivor than non survivor
group (Table 5).
Discussion
There are some widely used prognostic guidelines for
CAP. These systems appear to be useful in assisting physi-
cians to make more rational decisions regarding the need
for admission [13-15]. Patient mortalities in the risk
groups 3–5 on A-DROP and CURB-65, and IV-V on PSI
have previously been reported as 11.5–23.3%, 11.6–21.0%
and 12.5–29.2%, respectively [16-19]. A striking fact is that
the majority of the PCP patients were categorized as mild
Table 4 Comparison of the prognostic accuracy of the A-
DROP system and CURB-65 score and PSI
Sensitivity for mortality, %
A-DROP scores 3–5 12.5
CURB-65 scores 3–5 0
PSI risk classes IV- V 87.5
Specificity for mortality, %
A-DROP scores 3–5 84.6
CURB-65 scores 3–5 84.6
PSI risk classes IV- V 46.2
Positive predictive values for mortality, %
A-DROP scores 3–5 33.3
CURB-65 scores 3–5 0
PSI risk classes IV- V 50
Negative predictive values for mortality, %
A-DROP scores 3–5 61.1
CURB-65 scores 3–5 57.9
PSI risk classes IV- V 85.7
*In PSI, relations of risk classes to net points are as follows:
I: 0, II: 1–70, III: 71–90, IV: 91–130, V: >131.
Table 4 legend - PCP, Pneumocystis pneumonia; PSI, pulmonary severity index.
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failure, and poor outcomes. We emphasize that mortality
prediction in PCP is not correct when these conventional
guidelines for CAP are applied, even when PCP develops







Age 69.4 (8.9) 74.9 (9.3) 0.193
BMI (kg/m2) 22.3 (3.5) 22.5 (1.7) 0.872
β-DG (pg/ml) 93.8 (161) 82 (64.2) 0.846
KL-6 (U/ml) 771 (461) 1588 (1417) 0.104
LDH (IU/l) 521 (276) 799 (329) 0.051
CRP (mg/dl) 8.22 (4.35) 9.62 (4.92) 0.502
Alb/BUN 0.211 (0.133) 0.119 (0.054) 0.078
Lymphocytes (/μl) 1203 (1011) 752 (389) 0.28
Neutrophils (/μl) 7181 (3012) 7511 (3083) 0.825
WBC (/μl) 9323 (3581) 8700 (3103) 0.7
Interval from admission to PCP diagnosis (days)
4 (2.83) 7.88 (3.56) 0.012
Interval from admission to start PCP-specific
treatment (days)
1.77 (2.74) 6.88 (4.67) 0.005
Results are means (SDs).
Table 5 legend - β-DG, (1→ 3)-β-D-glucan; BUN, blood urea nitrogen; BMI,
body mass index; CAP, community-acquired pneumonia; CRP, C-reactive
protein; KL-6, Krebs von den Lungen 6; LDH, lactate dehydrogenase; PCP,
Pneumocystis pneumonia; PSI, pulmonary severity index; WBC, white blood
cells.underestimate the severity of PCP as CAP. The important
issue is why these guidelines cannot correctly estimate
PCP severity. PCP without HIV infection shows quite dif-
ferent clinical pictures compared to PCP with HIV infec-
tion. PCP with HIV occurs slowly and gradually [20]. On
the other hand, PCP without HIV is typically more acute
and severe than when associated with AIDS [10], often
resulting in acute respiratory failure requiring a need for
mechanical ventilation. We suppose that this results
from the differences of pathologic mechanisms between
PCP with and without HIV. It is evident that PCP without
HIV is an allergic reaction originating from Pneumocystis
jirovecii. Pneumocystis elicits many kinds of immune
responses, including those by lymphocytes, macrophages,
neutrophils, dendritic cells, and epithelial cells [1,21].
There is now a considerable body of evidence showing that
immune and inflammatory responses to Pneumocystis can
have harmful as well as beneficial effects on host lungs.
Another reason why the mortality rate of PCP without
HIV remains high is presumably that it is difficult to
diagnose PCP according to nonspecific signs, symptoms
and/or no reliable culture. Bollée et al. documented that
the leading symptoms of PCP in HIV-uninfected cancer
patients were fever (85.7%), dyspnea (78.6%), cough
(57.1%), and all three symptoms (44.6%) on diagnosis [5],
and 14.3% of the patients showed only one symptom. In
our study, 4 out of 21 patients (19%) were asymptomatic.
In addition, 6/21 patients (28.6%) showed abnormality in
chest X-ray on admission. It is possible that steroids and
immunosuppressive drugs could mask fever and general
fatigue on the initial visit. We strongly believe that clini-
cians are unable to diagnose non-HIV PCP by clinical
picture or chest X-ray alone. The association with P. jiro-
vecii cysts has been reported in HIV-uninfected PCP to
be one tenth of that in HIV-PCP [4]. Therefore, the sen-
sitivity of conventional staining methods for diagnosis of
HIV-uninfected PCP is lower than that for PCP with
HIV. Our study demonstrated the sensitivity of conven-
tional staining to be 23.8%. While Diff-Quik staining is
highly sensitive, it requires considerable technical expertise
[22]. It is likely that physicians are unable to diagnose PCP
without HIV soon enough due to the reasons mentioned
above.
A clue for making the early diagnosis of PCP is serum
β-D-gulcan (β-DG) and chest CT findings. Tasaka et al.
reported the β-DG could be a serum indicator for the
diagnosis of PCP with the cut-off value of 31 pg/ml
[23,24]. In our study, the sensitivity of β-DG in diagnos-
ing PCP was 10/21 (47.6%) setting the cut-off value at
31 pg/ml. We suggest that testing β-DG is effective for
diagnosis of PCP. In testing, BAL is also well known to
be more sensitive than IS, as many physicians previously
reported [23,25]. In terms of a radiological approach,
high resolution computed tomography (HRCT) should
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that chest CT shows ground glass appearance with a
panlobular pattern or so-called crazy paving appearance
in PCP patients [26,27]. These findings are also found in
viral pneumonias, mycoplasmal pneumonia, alveolar
hemorrhage, methotrexate pneumonia, and others. How-
ever, where the patient’s background and characteristics
are conducive, the presence of PCP should be suspected.
Conventional guidelines for CAP have recommended
that clinical outcomes should be evaluated three days
after initial therapy has been started [13,28-33]. In our
study, 12 of the 13 (92.3%) patients who received accurate
anti-PCP therapy within 3 days from initial visit were
cured. Ten of the 12 (83.3%) patients received empiric
therapy for PCP based on patient characteristics, labora-
tory data and radiological findings on HRCT. On the other
hand, 7 of the 8 (87.5%) patients who received anti-PCP
therapy that was initiated after day 4 died. PCP without
HIV tends to develop acute respiratory failure and results
in a more severe, acute form of acute respiratory distress
syndrome (ARDS) than PCP with HIV. Thus, only three
days of doctor’s delay in starting PCP therapy could be
fatal as our study showed.
The limitation of our study is that it is a retrospective
analysis in a very small population. Retrospective studies
may be less reliable in terms of the data collected, par-
ticularly for data such as physical examination. A pro-
spective study should be carried out and with more
cases.
Conclusions
In conclusion, we suggest that conventional prognostic
guidelines for CAP might underestimate the severity of
HIV-uninfected PCP. Physicians should be aware of the
possibility that PCP may occur in non-HIV patients hav-
ing malignancy or rheumatic disease, receiving steroid
and/or immunosuppressive therapy. The most important
factor for improving the mortality of PCP without HIV
could be the time when anti-PCP therapy is started.
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